<DOC>
	<DOCNO>NCT00885066</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose gemcitabine give together capecitabine erlotinib treat patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine , Capecitabine , Erlotinib Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum-tolerated dose combination gemcitabine hydrochloride , capecitabine , erlotinib hydrochloride patient advance pancreatic cancer . Secondary - Analyze limit toxicity accord CTC . - Analyze toxicity accord CTC . - Determine recommend dose . - Determine pharmacokinetic dosage three drug . - Analyze interaction drug . OUTLINE : This multicenter study . Patients receive one course chemotherapy comprise gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , oral capecitabine twice daily day 1-21 , oral erlotinib hydrochloride daily day 1-28 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Advanced disease No standard curative therapy available Must receive prior firstline chemotherapy No brain metastasis PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 8 week ANC ≥ 1.5 x 10^9/ L Platelet count ≥ 130 x 10^9/ L Hemoglobin ≥ 10 g/dL Liver transaminases ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN presence liver metastasis ) Bilirubin ≤ 1.5 time ULN Creatinine ≤ 130 mmol/L OR creatinine clearance &gt; 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No intolerance hypersensitivity drug test No history interstitial lung disease No history severe cardiac disease No serious uncontrolled infection No rare hereditary disorder , i.e. , galactosemia , lactase deficiency , malabsorption glucose galactose syndrome Must deprive liberty guardianship Must probation PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior erlotinib hydrochloride No concurrent potent inducer inhibitor cytochrome P450 CYP3A4 More 14 day since participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>